Jeff Yass’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-140,764
| Closed | -$859K | – | 14451 |
|
|
2021
Q3 | $859K | Sell |
140,764
-32,294
| -19% | -$201K | ﹤0.01% | 7964 |
|
|
2021
Q2 | $1.42M | Buy |
173,058
+117,300
| +210% | +$998K | ﹤0.01% | 6803 |
|
|
2021
Q1 | $499K | Buy |
55,758
+30,717
| +123% | +$352K | ﹤0.01% | 9479 |
|
|
2020
Q4 | $289K | Sell |
25,041
-7,969
| -24% | -$92.6K | ﹤0.01% | 9351 |
|
|
2020
Q3 | $344K | Sell |
33,010
-36,675
| -53% | -$449K | ﹤0.01% | 8436 |
|
|
2020
Q2 | $916K | Sell |
69,685
-6,076
| -8% | -$63K | ﹤0.01% | 6120 |
|
|
2020
Q1 | $596K | Sell |
75,761
-39,507
| -34% | -$595K | ﹤0.01% | 6544 |
|
|
2019
Q4 | $2.39M | Sell |
115,268
-63,721
| -36% | -$1.07M | ﹤0.01% | 4032 |
|
|
2019
Q3 | $2.45M | Buy |
178,989
+10,311
| +6% | +$122K | ﹤0.01% | 3821 |
|
|
2019
Q2 | $2.08M | Buy |
168,678
+117,211
| +228% | +$1.35M | ﹤0.01% | 4101 |
|
|
2019
Q1 | $642K | Buy |
+51,467
| New | +$688K | ﹤0.01% | 5823 |
|
|
2018
Q1 | – | Sell |
-100,280
| Closed | -$2.45M | – | 10517 |
|
|
2017
Q4 | $2.51M | Buy |
+100,280
| New | +$2.46M | ﹤0.01% | 3516 |
|
|
2017
Q1 | – | Sell |
-70,974
| Closed | -$1.45M | – | 10361 |
|
|
2016
Q4 | $1.35M | Buy |
+70,974
| New | +$1.36M | ﹤0.01% | 4892 |
|
Jeff Yass's FLXN Position: Q4 2021 in Review
Jeff Yass sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 140,764 shares — an estimated $859K sold.
Jeff Yass first reported a position in FLXN in Q4 2016 and held it in 13 quarters. The position peaked at $2.51M in Q4 2017. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Jeff Yass reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Jeff Yass sold 140,764 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $859K.
- Jeff Yass first reported a position in Flexion Therapeutics, Inc. in Q4 2016 and held it in 13 quarters.
- Jeff Yass's Flexion Therapeutics, Inc. position peaked at $2.51M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.